Welcome to the e-CCO Library Archive!
P291
Sacroiliitis is under-recognised in inflammatory bowel disease and is associated with previous arthritis and inflammatory Crohn’s phenotype
O. Kelly*1, N. Li1, J. Chan2, R. Inman2, M. Silverberg1
1Mount Sinai Hospital, Centre for Inflammatory Bowel Disease. Suite 437, Toronto, Canada, 2University of Toronto, Rheumatology, Toronto, Canada
P292
Development of a predictive model for the diagnosis of Crohn’s disease when ileocolonoscopy is insufficient: a multicentre study
P. Boal Carvalho*1, M. Marques2, B. Rosa1, H. Cardoso2, F. Machado3, G. Macedo2, J. Cotter1, 4, 5
1Hospital Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 2Hospital de São João, Gastroenterology, Porto, Portugal, 3ACES Porto Ocidental, Public Health Unit, Porto, Portugal, 4University of Minho, Life and Health Research Institute, Braga/Guimarães, Portugal, 5PT Government Associate Laboratory, ICVS/3B’s, Braga/Guimarães, Portugal
P293
Delayed timing of post-operative colonoscopy within 1 year does not predict a more severe Rutgeerts score
S. Singh*1, J. Pang2, 3, C. Seow1, 2, 4, Y. Leung1, 2, 4, K. Novak1, 2, 4, R. Panaccione1, 2, 4, G. Kaplan1, 2, 3, 4
1University of Calgary, Gastroenterology, Calgary, Canada, 2University of Calgary, Foothills Campus, Department of Medicine, Calgary, Canada, 3University of Calgary, Community Health Sciences, Calgary, Canada, 4University of Calgary, Inflammatory Bowel Diseases Clinic, Calgary, Canada
P294
Distress in inflammatory bowel disease: development of a new assessment tool
L. Dibley*1, W. Czuber-Dochan1, S. Woodward1, P. Bassett2, J. Sturt1, C. Norton1
1King’s College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom, 2Statsconsultancy, Medical Statistician, Amersham, United Kingdom
P295
The Ulcerative Colitis Endoscopic Index of Severity is useful to predict medium- to long-term prognosis in ulcerative colitis patients with clinical remission
M. Arai*1, M. Naganuma1, S. Sugimoto1, H. Kiyohara1, K. Ohno1, M. Mutaguchi1, K. Mori1, K. Nanki1, S. Mizuno1, R. Bessho1, Y. Nakazato2, N. Inoue3, H. Ogata2, Y. Iwao2, T. Kanai1
1Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan, 2Keio University School of Medicine, Centre for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan, 3Keio University School of Medicine, Centre for Preventive Medicine, Tokyo, Japan
P296
Evaluation of the new liaison faecal calprotectin assay
N. Hammoudi1, H. Manceau2, C. Stefanescu1, D. Debuyser2, Y. Bouhnik1, 3, H. Puy2, 3, K. Peoc’h*2, 3
1APHP HUPNVS Beaujon, Department of Gastroenterology and Nutrition, Clichy, France, 2APHP, HUPNVS, Hopital Beaujon, Biochemistry, Clichy, France, 3Université Paris Diderot, Faculté Xavier Bichat, UMRs INSERM 1149, CRI, Paris, France
P297
Ulcerative colitis and proximal extension of the disease: a sub-group with worse prognosis?
P. Sousa*, D. Martins, J. Pinho, R. Araújo, E. Cancela, A. Castanheira, P. Ministro, A. Silva
Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal
P298
Comparison of the familial and sporadic cases of inflammatory bowel diseases in long-term follow-up regarding step-up treatment, clinical, and biochemical parameters
S. Bozcan*, I. Hatemi, Y. Erzin, G. Ayan, A. Satman, T. Gundogdu, K. Atay, N. Demir, A.F. Celik
Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey
P299
Is quality of life different between Crohn’s disease patients submitted to early surgery or immunosuppression?
R. Barosa*, M. Patita, G. Nunes, C. Carreira, C. Cruz, C. Boal, A. I. Vieira, J. Freitas
Hospital Garcia de Orta, Gastroenterology, Almada, Portugal
P300
Predictors of a second surgery in patients with Crohn’s disease: are we following the right path?
S. Raimundo Fernandes*, S. Bernardo, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa
Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal
P301
Gender influencing attitudes to inflammatory bowel disease: a questionnaire investigating the effect of IBD on body-image, sexual function, and family planning
K. Boland*, M. Forry, N. Godwin, E. Tatro, F. E. Murray, G. C. Harewood, S. Patchett, A. O Toole
Beaumont Hospital, Department of Gastroenterology and Hepatology, Dublin, Ireland
P302
Faecal calprotectin correlates with small bowel inflammatory activity detected by capsule endoscopy in patients with established Crohn’s disease
M. Barbosa*1, S. Monteiro1, T. Gonçalves1, M. J. Moreira1, B. Rosa1, J. Cotter1, 2, 3
1Hospital da Senhora da Oliveira, Gastroenterology, Guimaraes, Portugal, 2Instituto de Investigação em Ciências da Vida e da Saúde, Universidade do Minho, Braga, Portugal, 3Laboratório Associado ICVS/3B´s, Braga, Portugal
P303
Factors associated with the development of extraintestinal manifestations in patients with ulcerative colitis
J. Yamamoto-Furusho*1, G. Sanchez-Morales2
1IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico
P304
Patients with perianal Crohn’s disease have poor disease outcomes after primary bowel resection
Y. M. Han*1, J. W. Kim2, J. H. Kim1, S.-J. Koh2, H. Yoon3, C. Lee4, J. P. Im1, J. S. Kim1
1Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 2Seoul National University Boramae Hospital, Department of Internal Medicine, Seoul, South Korea, 3Seoul National University Bundang Hospital, Departments of Internal Medicine, Seongnam, South Korea, 4Healthcare System Gangnam Centre, Seoul National University Hospital, Department of Internal Medicine, Division of Gastroenterology, Seoul, South Korea
P305
No increased risk for infections with thiopurine-induced leukopenia in inflammatory bowel disease patients without a variant in thiopurine S-methyltransferase
M. Broekman*1, M. Coenen2, C. van Marrewijk2, G. Wanten1, L. Derijks3, S. Vermeulen2, 4, D. Wong5, O. Klungel6, A. Verbeek4, P. Hooymans5, H. Scheffer2, H.-J. Guchelaar7, D. de Jong1
1Radboud University Medical Centre, Department of Gastroenterology, Nijmegen, Netherlands, 2Radboud University Medical Centre, Department of Human Genetics, Nijmegen, Netherlands, 3Maxima Medical Centre Loc. Veldhoven, Department of Gastroenterology and Hepatology, Veldhoven, Netherlands, 4Radboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, Netherlands, 5Zuyderland Medical Centre, Department of Clinical Pharmacy, Pharmacology and Toxicology, Sittard, Netherlands, 6Utrecht University, Departement of Pharmacoepidemiology and Clinical Pharmacotherapy, Utrecht, Netherlands, 7Leiden University Medical Centre, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands
P306
The real-life experience of vedolizumab efficacy and safety in ulcerative colitis: a prospective observational multicentre cohort study
A. Amiot*1, L. Peyrin-Biroulet2, C. Stefanescu3, J. C. Grimaud4, J. Filippi5, B. Pariente6, X. Roblin7, R. Altwegg8, D. Laharie9, P. Marteau10, A. Buisson11, C. Trang-Poisson12, S. Nancey13, G. Savoye14, S. Viennot15, H. Brixi-Benmansour16, F. Carbonnel17, Y. Bouhnik3
1Henri Mondor Hospital, Gastroenterology, Creteil, France, 2CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, 3APHP Beaujon, Department of Gastroenterology, Clichy, France, 4Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, 5Archet 2 Hospital, Department of Gastroenterology, Nice, France, 6CHRU Lille, Department of Gastroenterology, Lille, France, 7University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 8CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, 9CHU Bordeaux, Department of Gastroenterology, Bordeaux, France, 10Hospital Lariboisière, Department of Gastroenterology, Paris, France, 11CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, 12CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, 13Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, 14CHU Rouen, Department of Gastroenterology, Rouen, France, 15Hospital Cote de Nacre, Department of Gastroenterology, Caen Cede, France, 16Robert Debre Hospital, Department of Gastroenterology, Reims, France, 17CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France
P307
Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension
W. Reinisch*1, P. Gibson2, W. J. Sandborn3, B. Feagan4, C. Marano5, R. Strauss5, J. Johanns5, H. Zhang5, L. Padgett5, O. J. Adedokun5, J.-F. Colombel6, J. Collins7, P. Rutgeerts8, D. Tarabar9
1Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, 2Alfred Hospital, Melbourne, Australia, 3University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, 4Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 5Janssen R & D, LLC, Spring House, Pennsylvania, United States, 6Mount Sinai, Icahn School of Medicine, New York, New York, United States, 7Oregon Health Sciences University, Department of Gastroenterology, Portland, Oregon, United States, 8University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, 9Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia
P308
Predictors of loss of response to adalimumab therapy: the importance of therapeutic drug monitoring in inflammatory bowel diseases
Z. Kurti*1, Z. Vegh1, M. Rutka2, L. Gonczi1, K. Farkas2, K. Gecse1, P. A. Golovics1, B. Szalay3, T. Molnar2, P. Lakatos1
1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary
P309
High infliximab trough levels are associated with better control of inflammation in inflammatory bowel disease
D. Drobne*1, T. Kurent1, P. Rajar2, M. Slak3, M. Kozelj1, G. Novak1, N. Smrekar1, S. Plut1, A. Smid1, J. Osredkar4, B. Stabuc1, I. Ferkolj1
1University Medical Centre Ljubljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia, 2University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia, 3Faculty of Pharmacy, Ljubljana, Slovenia, 4University Medical Centre Ljubljana, Clinical Institute of clinical chemistry and biochemistry, Ljubljana, Slovenia
P310
Patient-reported quality of life during golimumab induction for moderate-to-severe ulcerative colitis in the United Kingdom: results from the GO-COLITIS study
P. Irving*1, C. Probert2, D. R. Gaya3, P. J. Hamlin4, S. Sebastian5, G. Gillespie6, H. Tate6, C. Wheeler6
1Guy’s and St Thomas’ Hospitals, London, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom, 3Glasgow Royal Infirmary, Glasgow, United Kingdom, 4Leeds Teaching Hospitals Trust, Leeds, United Kingdom, 5Hull & East Yorkshire NHS Trust, Hull, United Kingdom, 6MSD UK, Hoddesdon, United Kingdom